Remdesivir News and Research

RSS

Marine resources could be promising drug candidates against SARS-CoV-2 Omicron

A recent review paper, published in the MDPI’s specialized journal COVID, highlights key features of the Omicron variant of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – and examines the potential and roadblocks in using renewable marine resources in the fight against the coronavirus disease 2019 (COVID-19).

24 Apr 2022

Interleukin-6 levels predict early withdrawal of COVID-19 patients from mechanical ventilation

Researchers reported that plasma IL-6 levels in patients with ARDS due to COVID-19 could predict early withdrawal from mechanical ventilation.

22 Apr 2022

Antibody-based treatment, endogenous immune responses, and within-host SARS-CoV-2 evolution in immunocompromised patients

Researchers investigated the interplay of all the factors responsible for within-host evolution of SARS-CoV-2 variants in immunocompromised patients.

21 Apr 2022

Why cheap, older drugs that might treat covid never get out of the lab

In March 2020, Dr. Joseph Vinetz left the contemplative world of his Yale University infectious-disease laboratory and plunged into the covid ward at Yale New Haven Hospital, joining an army of health care workers who struggled to treat the deadly viral disease.

19 Apr 2022

New, longest documented case of persistent acute SARS-CoV-2 infection

Researchers describe a 16-month-old case of SARS-CoV-2 infection in an immunocompromised individual.

18 Apr 2022

Avasimibe inhibits SARS-CoV-2 and boosts T-cell responses

Researchers demonstrate that avasimibe-mediated inhibition of ACAT blocks the entry and fusion of SARS-CoV-2 in different cell types.

18 Apr 2022

Study finds dexamethasone and remdesivir treatment in hospitalized COVID-19 patients is associated with reduced neurological complications

Researchers investigated the potential of therapeutic drugs, remdesivir and dexamethasone, when used alone or in combination on neurological complications that arise in COVID-19 affected individuals.

14 Apr 2022

COVID-19 may affect a group of biochemical reactions called one-carbon metabolism

A new study addresses the relationship between SARS-CoV-2 to the metabolism of one-carbon molecules in the host, suggesting new therapeutic pathways.

13 Apr 2022

Scientific statement from the American Heart Association on COVID-19 and cardiovascular complications in children and adolescents

A recent scientific statement published in Circulation reviewed the current knowledge on COVID-19.

13 Apr 2022

Heart complications uncommon for children and young adults after SARS-CoV-2 infection

Heart complications are uncommon, yet treatable for children and young adults after COVID-19 disease or SARS-CoV-2 infection, according to a new scientific statement from the American Heart Association that details what has been learned about how to treat, manage and even prevent cardiovascular complications from the SARS-CoV-2 virus in youth.

12 Apr 2022

S-Nitrosylation of ACE2 inhibits binding of SARS-CoV-2 spike protein

In a recent study posted to the bioRxiv* preprint server, researchers developed aminoadamantane nitrates compounds that inhibit the ion channels formed by the envelope (E) protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and enable targeted drug delivery of nitric oxide (NO)-related group for S-nitrosylation of host angiotensin-converting enzyme 2 (ACE2), which would inhibit ACE2 binding with the viral spike (S) protein and thereby inhibit viral replication in the host.

11 Apr 2022

Immunocompromised hosts with Delta/Omicron co-infections

A recent study posted to the medRxiv* preprint server examined clinical cases of co-infections of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta/Omicron variants and Omicron BA.1/ BA.2 sublineages in immunocompromised (IC) patients.

10 Apr 2022

Challenges, unmet needs and future opportunities in COVID-19 therapeutics

In a recent article published in the journal Proceedings of the National Academy of Sciences (PNAS), researchers reviewed the present-day therapeutic landscape of coronavirus disease 2019 (COVID-19) and addressed future opportunities to overcome challenges that hinder drug development and improve the global preparedness for future pandemics.

10 Apr 2022

Study explores broad-spectrum, host-acting antiviral strategy to treat SARS-CoV-2

A new study investigates the combination of two small molecules that target the host cells and reports a synergistic antiviral activity in vitro against SARS-CoV-2.

7 Apr 2022

Value of information analysis on clinical trial data to help approve or reject new COVID-19 drugs

Researchers quantified the cost-effective health benefits of pursuing further research or approving or rejecting COVID-19 drugs based on the existing research using a novel method called VOI analysis.

4 Apr 2022

Research demonstrates potential of local siRNA delivery as COVID antiviral therapy in the lung

Scientists develop a formulation for the pulmonary administration of siRNA. The aim was to suppress the replication of SARS-CoV-2.

3 Apr 2022

An in-depth analysis of pathogenesis of SARS-CoV-2 and therapeutic options for COVID-19

Scientists discuss the pathogenic characteristics of SARS-CoV-2 and available therapeutic interventions for treating COVID-19.

3 Apr 2022

Study explores molecular mechanisms underlying SARS-CoV-2 infection of macrophages and the induction of pro-inflammatory cytokines

Researchers examined the role of sialic acid-binding immunoglobulin-type lectins-1, a myeloid cell-specific receptor, in facilitating SARS-CoV-2 infection of ACE2-deficient macrophages and its effect on pro-inflammatory cytokine expression.

1 Apr 2022

Impact of racial disparities on COVID-19 outcomes

A new study investigated the racial disparities in COVID-19 outcomes in Black and White patients diagnosed with cancer.

31 Mar 2022

Chemical in leafy greens could prevent infections by coronaviruses including SARS-CoV-2

Researchers discuss the use of the isothiocyanate sulforaphane for the treatment of both SARS-CoV-2 and HCoV-OC43 infections.

30 Mar 2022